In this context, a short-termed and limited dose of an ABCG2-specific inhibitor during intra-operative PDD of human brain tumors may be recommended as a practical approach to enhance the efficacy of PDD at border regions of malignant gliomas, and to reduce the risk of drug-induced adverse reactions for cancer patients. The gene discussed is ABCG2; the disease is brain neoplasm.